Published in Clin Cancer Res on April 15, 2004
The human keratins: biology and pathology. Histochem Cell Biol (2008) 5.13
Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics (2012) 2.66
Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest (2009) 2.34
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Keratins in health and cancer: more than mere epithelial cell markers. Oncogene (2010) 1.61
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol (2011) 1.60
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res (2008) 1.59
Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells. Clin Transl Med (2015) 1.45
Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer (2006) 1.28
Negative regulation of the expressions of cytokeratins 8 and 19 by SLUG repressor protein in human breast cells. Biochem Biophys Res Commun (2005) 1.07
Circulating tumor cells, enumeration and beyond. Cancers (Basel) (2010) 1.03
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer (2007) 1.03
Understanding the role of keratins 8 and 18 in neoplastic potential of breast cancer derived cell lines. PLoS One (2013) 0.92
Cisplatin induces differentiation of breast cancer cells. Front Oncol (2013) 0.92
Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer (2009) 0.92
Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease. Breast Cancer Res Treat (2012) 0.89
Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells. Oncotarget (2015) 0.88
Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model. Oncotarget (2015) 0.86
Lysine 394 is a novel Rad6B-induced ubiquitination site on beta-catenin. Biochim Biophys Acta (2012) 0.84
Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol (2012) 0.84
Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities. Cancer Med (2016) 0.81
Clinical significance of disseminated tumour cells in non-small cell lung cancer. Br J Cancer (2013) 0.81
Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma. J Cancer Res Clin Oncol (2009) 0.80
Keratin 18 attenuates estrogen receptor alpha-mediated signaling by sequestering LRP16 in cytoplasm. BMC Cell Biol (2009) 0.79
Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction. Pharm Res (2012) 0.79
Clinical significance of cytokeratin positive cells in bone marrow of gastric cancer patients. J Cancer Res Clin Oncol (2007) 0.79
EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation. PLoS One (2016) 0.77
Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget (2016) 0.77
Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer. J Cancer Res Clin Oncol (2016) 0.76
High KRT8 expression promotes tumor progression and metastasis of Gastric Cancer. Cancer Sci (2016) 0.75
Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker. J Patient Cent Res Rev (2014) 0.75
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res (2008) 2.06
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 1.79
Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71
Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation (2004) 1.68
SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res (2006) 1.66
Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res (2012) 1.63
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst (2005) 1.60
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol (2002) 1.59
Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res (2011) 1.58
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol (2006) 1.56
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56
Biologic challenges in the detection of circulating tumor cells. Cancer Res (2012) 1.55
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer (2005) 1.55
Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2012) 1.53
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res (2003) 1.53
Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res (2006) 1.52
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50
Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate (2014) 1.50
Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther (2007) 1.50
Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res (2007) 1.49
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol (2002) 1.48
Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev (2012) 1.47
Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology (2008) 1.47
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol (2004) 1.44
Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol (2003) 1.43
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res (2013) 1.42
E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene (2004) 1.40
Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res (2004) 1.40
Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res (2007) 1.36
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest (2004) 1.35
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res (2009) 1.31
Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res (2004) 1.31